FDA
-
-
-
-
-
-
-
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
-
-
-
-
-
-
-
Denali Therapeutics Inc. (DNLI) PT Raised to $40 at Oppenheimer
-
-
-
-
-
-
-
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
-
-
-
-
-
-
-
Jefferies on Denali (DNLI): 'Net-net, we remain 70-80%+ confident in an FDA approval by the April 5, 2026 PDUFA date'
-
-
-
-
-
-
-
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
-
-
-
-
-
-
-
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
-
-
-
-
-
-
-
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
-
327,806 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

